# Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

> **NCT03455309** · PHASE2 · COMPLETED · sponsor: **NovaDigm Therapeutics, Inc.** · enrollment: 382 (actual)

## Conditions studied

- Staphylococcus Aureus

## Interventions

- **BIOLOGICAL:** NDV-3A
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03455309
- **Lead sponsor:** NovaDigm Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-30
- **Primary completion:** 2019-07-19
- **Final completion:** 2019-10-15
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2020-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455309, "Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03455309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*